BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 22
• 23
• 29
• 30

• Drug Development

  Curis, Inc. Announces Genentech, Inc.’s Initiation of Phase II Clinical Trial in Advanced Ovarian Cancer with Hedgehog Pathway Inhibitor

  December 8, 2008

   · 

  1 min read
• Genetown

  Curis, Inc. to Present at RBC Capital Markets 2008 Healthcare Conference

  December 8, 2008

   · 

  1 min read
• BioMidwest

  CyDex Pharmaceuticals Receives Orphan-Drug Designation for Melphalan

  December 8, 2008

   · 

  1 min read
• Drug Development

  GlycoMimetics, Inc. to Present New Results of Lead Candidate in Additional Animal Models of Sickle Cell Disease at American Society of Hematology Annual Meeting

  December 8, 2008

   · 

  1 min read
• Biotech Bay

  Johnson & Johnson Pharmaceutical Research & Development, LLC (CA) Release: Rivaroxaban Reduces Symptomatic VTE & Death Following Knee or Hip Replacement Surgery by More Than 50% Compared to Enoxaparin in Pooled Analysis of the RECORD Clinical Trial Progra

  December 8, 2008

   · 

  1 min read
• Drug Development

  Incyte Corporation’s Selective JAK1 / 2 Inhibitor, INCB18424, Demonstrates Rapid and Durable Clinical Benefits in Myelofibrosis Patients

  December 8, 2008

   · 

  1 min read
• Lone Star Bio

  Introgen Therapeutics, Inc. Common Stock to be Delisted from the Nasdaq Stock Market

  December 8, 2008

   · 

  1 min read
• Drug Development

  Ligand Pharmaceuticals Inc. Presents Positive LGD-4665 Clinical Trial Results at the American Society of Hematology Annual Meeting

  December 8, 2008

   · 

  1 min read
• Drug Development

  Micromet Data Presented at American Society of Hematology Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias

  December 8, 2008

   · 

  6 min read
• Business

  IDEXX Laboratories, Inc. Names William Brown Corporate Vice President

  December 8, 2008

   · 

  2 min read